Retaining Participants in Longitudinal Studies of Alzheimer's Disease.


Journal

Journal of Alzheimer's disease : JAD
ISSN: 1875-8908
Titre abrégé: J Alzheimers Dis
Pays: Netherlands
ID NLM: 9814863

Informations de publication

Date de publication:
2022
Historique:
pubmed: 12 4 2022
medline: 25 5 2022
entrez: 11 4 2022
Statut: ppublish

Résumé

Retention of study participants is essential to advancing Alzheimer's disease (AD) research and developing therapeutic interventions. However, recent multi-year AD studies have lost 10% to 54% of participants. We surveyed a random sample of 443 participants (Clinical Dementia Rating [CDR]≤1) at four Alzheimer Disease Research Centers to elucidate perceived facilitators and barriers to continued participation in longitudinal AD research. Reasons for participation were characterized with factor analysis. Effects of perceived fulfillment of one's own goals and complaints on attendance and likelihood of dropout were estimated with logistic regression models. Open-ended responses suggesting study improvements were analyzed with a Latent Dirichlet Allocation topic model. Factor analyses revealed two categories, personal benefit and altruism, as drivers of continued participation. Participants with cognitive impairment (CDR > 0) emphasized personal benefits more than societal benefits. Participants with higher trust in medical researchers were more likely to emphasize broader social benefits. A minority endorsed any complaints. Higher perceived fulfillment of one's own goals and fewer complaints were related to higher attendance and lower likelihood of dropout. Facilitators included access to medical center support and/or future treatment, learning about AD and memory concerns, and enjoying time with staff. Participants' suggestions emphasized more feedback about individual test results and AD research. The results confirmed previously identified facilitators and barriers. Two new areas, improved communication about individual test results and greater feedback about AD research, emerged as the primary factors to improve participation.

Sections du résumé

BACKGROUND
Retention of study participants is essential to advancing Alzheimer's disease (AD) research and developing therapeutic interventions. However, recent multi-year AD studies have lost 10% to 54% of participants.
OBJECTIVE
We surveyed a random sample of 443 participants (Clinical Dementia Rating [CDR]≤1) at four Alzheimer Disease Research Centers to elucidate perceived facilitators and barriers to continued participation in longitudinal AD research.
METHODS
Reasons for participation were characterized with factor analysis. Effects of perceived fulfillment of one's own goals and complaints on attendance and likelihood of dropout were estimated with logistic regression models. Open-ended responses suggesting study improvements were analyzed with a Latent Dirichlet Allocation topic model.
RESULTS
Factor analyses revealed two categories, personal benefit and altruism, as drivers of continued participation. Participants with cognitive impairment (CDR > 0) emphasized personal benefits more than societal benefits. Participants with higher trust in medical researchers were more likely to emphasize broader social benefits. A minority endorsed any complaints. Higher perceived fulfillment of one's own goals and fewer complaints were related to higher attendance and lower likelihood of dropout. Facilitators included access to medical center support and/or future treatment, learning about AD and memory concerns, and enjoying time with staff. Participants' suggestions emphasized more feedback about individual test results and AD research.
CONCLUSION
The results confirmed previously identified facilitators and barriers. Two new areas, improved communication about individual test results and greater feedback about AD research, emerged as the primary factors to improve participation.

Identifiants

pubmed: 35404282
pii: JAD215710
doi: 10.3233/JAD-215710
pmc: PMC9673904
mid: NIHMS1814912
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

945-955

Subventions

Organisme : NIA NIH HHS
ID : P30 AG066468
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG066519
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG016976
Pays : United States
Organisme : NIA NIH HHS
ID : U24 AG072122
Pays : United States

Références

J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
J Gerontol Geriatr Res. 2014 Oct;3(4):
pubmed: 25520902
Alzheimers Dement. 2020 Dec;16(12):1734-1744
pubmed: 33034414
Clin Transl Sci. 2015 Oct;8(5):460-6
pubmed: 25974328
J Nutr Health Aging. 2012 Apr;16(4):339-45
pubmed: 22499454
J Empir Res Hum Res Ethics. 2014 Oct;9(4):46-9
pubmed: 26125079
Gerontologist. 2015 Oct;55(5):845-53
pubmed: 22899424
Int Psychogeriatr. 2021 Aug;33(8):767-778
pubmed: 32301414
Curr Alzheimer Res. 2017;14(4):426-440
pubmed: 27697063
Genome Med. 2015 Jan 31;7(1):10
pubmed: 25642295
Alzheimers Dement (N Y). 2016 Oct 15;3(1):57-64
pubmed: 29067319
Trials. 2020 Mar 12;21(1):259
pubmed: 32164790
AIDS Educ Prev. 2003 Jun;15(3):269-81
pubmed: 12866838
Image J Nurs Sch. 1997 Spring;29(1):59-64
pubmed: 9127542
Alzheimers Dement. 2011 May;7(3):280-92
pubmed: 21514248
Health Aff (Millwood). 2014 Apr;33(4):574-9
pubmed: 24711317
Neurology. 2013 May 7;80(19):1778-83
pubmed: 23390181
Alzheimer Dis Assoc Disord. 2002;16 Suppl 2:S46-9
pubmed: 12351914
Gerontologist. 2003 Feb;43(1):45-51
pubmed: 12604745
Am J Geriatr Psychiatry. 2017 Oct;25(10):1150-1159
pubmed: 28554539
Alzheimer Dis Assoc Disord. 2018 Oct-Dec;32(4):351-358
pubmed: 30376508
Bioethics. 2007 Jun;21(5):263-9
pubmed: 17845471
Aging Clin Exp Res. 2019 Sep;31(9):1283-1297
pubmed: 30535620
Alzheimer Dis Assoc Disord. 2010 Jul-Sep;24 Suppl:S19-23
pubmed: 20711060
J Am Geriatr Soc. 2008 Dec;56(12):2340-8
pubmed: 19093934
J Alzheimers Dis. 2021;80(3):927-940
pubmed: 33612540
Gerontologist. 2017 Apr 1;57(2):348-358
pubmed: 26553736
Alzheimers Dement. 2020 May;16(5):789-796
pubmed: 32202077
Neurology. 2019 Jul 23;93(4):e322-e333
pubmed: 31289148
Alzheimer Dis Assoc Disord. 2007 Jul-Sep;21(3):249-58
pubmed: 17804958
Neurology. 2013 Jan 15;80(3):282-8
pubmed: 23255824
Front Aging Neurosci. 2019 May 31;11:125
pubmed: 31214014
J Alzheimers Dis. 2008 Oct;15(2):327-38
pubmed: 18953117
Alzheimers Res Ther. 2021 Jan 8;13(1):16
pubmed: 33419457
Alzheimers Res Ther. 2010 Dec 21;2(6):34
pubmed: 21172069
Curr Alzheimer Res. 2011 Jun;8(4):421-33
pubmed: 21244348
Am J Alzheimers Dis Other Demen. 2011 May;26(3):227-34
pubmed: 21343152
Curr Alzheimer Res. 2019;16(5):458-471
pubmed: 30907319
J Aging Health. 2004 Nov;16(5 Suppl):9S-17S
pubmed: 15448284
Alzheimer Dis Assoc Disord. 2019 Oct-Dec;33(4):299-306
pubmed: 31567302
Gerontology. 2013;59(2):114-21
pubmed: 23146954
J Aging Health. 2004 Nov;16(5 Suppl):93S-123S
pubmed: 15448289
Neurology. 2006 Nov 14;67(9 Suppl 3):S14-6
pubmed: 17101928
Neurology. 2012 May 1;78(18):1376-82
pubmed: 22491869
Alzheimers Dement. 2019 Dec;15(12):1533-1545
pubmed: 31601516

Auteurs

Matthew Gabel (M)

Department of Political Science, Washington University in St. Louis, St. Louis, MO, USA.
Knight Alzheimer Disease Research Center, Washington University in St. Louis, St. Louis, MO, USA.

Rebecca M Bollinger (RM)

School of Medicine, Washington University in St. Louis, St. Louis, MO, USA.

Dean W Coble (DW)

School of Medicine, Washington University in St. Louis, St. Louis, MO, USA.

Joshua D Grill (JD)

Institute for Memory Impairments and Neurological Disorders, Departments of Psychiatry & Human Behavior and Neurobiology & Behavior, University of California Irvine, Irvine, CA, USA.

Dorothy F Edwards (DF)

School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA.
Wisconsin Alzheimer's Disease Research Center, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA.

Jennifer H Lingler (JH)

School of Nursing, University of Pittsburgh, Pittsburgh, PA, USA.
Alzheimer's Disease Research Center, University of Pittsburgh, Pittsburgh, PA, USA.

Erin Chin (E)

School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA.

Susan L Stark (SL)

Knight Alzheimer Disease Research Center, Washington University in St. Louis, St. Louis, MO, USA.
School of Medicine, Washington University in St. Louis, St. Louis, MO, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH